Cargando…
Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases
Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582977/ https://www.ncbi.nlm.nih.gov/pubmed/32993066 http://dx.doi.org/10.3390/ijms21197100 |
_version_ | 1783599315150700544 |
---|---|
author | Rafael-Vidal, Carlos Pérez, Nair Altabás, Irene Garcia, Samuel Pego-Reigosa, Jose M. |
author_facet | Rafael-Vidal, Carlos Pérez, Nair Altabás, Irene Garcia, Samuel Pego-Reigosa, Jose M. |
author_sort | Rafael-Vidal, Carlos |
collection | PubMed |
description | Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option. |
format | Online Article Text |
id | pubmed-7582977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75829772020-10-28 Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases Rafael-Vidal, Carlos Pérez, Nair Altabás, Irene Garcia, Samuel Pego-Reigosa, Jose M. Int J Mol Sci Review Systemic rheumatic diseases are a heterogeneous group of autoimmune disorders that affect the connective tissue, characterized by the involvement of multiple organs, leading to disability, organ failure and premature mortality. Despite the advances in recent years, the therapeutic options for these diseases are still limited and some patients do not respond to the current treatments. Interleukin-17 (IL-17) is a cytokine essential in the defense against extracellular bacteria and fungi. Disruption of IL-17 homeostasis has been associated with the development and progression of rheumatic diseases, and the approval of different biological therapies targeting IL-17 for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has highlighted the key role of this cytokine. IL-17 has been also implicated in the pathogenesis of systemic rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS) and systemic sclerosis (SSc). The aim of this review is to summarize and discuss the most recent findings about the pathogenic role of IL-17 in systemic rheumatic and its potential use as a therapeutic option. MDPI 2020-09-26 /pmc/articles/PMC7582977/ /pubmed/32993066 http://dx.doi.org/10.3390/ijms21197100 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rafael-Vidal, Carlos Pérez, Nair Altabás, Irene Garcia, Samuel Pego-Reigosa, Jose M. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title_full | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title_fullStr | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title_full_unstemmed | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title_short | Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases |
title_sort | blocking il-17: a promising strategy in the treatment of systemic rheumatic diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582977/ https://www.ncbi.nlm.nih.gov/pubmed/32993066 http://dx.doi.org/10.3390/ijms21197100 |
work_keys_str_mv | AT rafaelvidalcarlos blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases AT pereznair blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases AT altabasirene blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases AT garciasamuel blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases AT pegoreigosajosem blockingil17apromisingstrategyinthetreatmentofsystemicrheumaticdiseases |